Copyright
©The Author(s) 2016.
World J Diabetes. Mar 25, 2016; 7(6): 122-133
Published online Mar 25, 2016. doi: 10.4239/wjd.v7.i6.122
Published online Mar 25, 2016. doi: 10.4239/wjd.v7.i6.122
Organ | Effect | Mechanism of action | Ref. |
Liver | Inhibition of anabolic pathways | Inhibition of fatty acid synthesis | [27] |
Inhibition of gluconeogenesis | |||
Stimulation of ATP synthesis | Stimulation of Mitochondrial oxidative phosphorylation | [27] | |
Skeletal muscle | Regulation of energy expenditure during exercise | Favours the transition from glycolitic to oxidative skeletal muscle fibers | [28] |
Regulation of myocitic uptake and oxidation of fatty acids | [21] | ||
Enhanced glucose uptake via an increase in GLUT4 expression | [21] | ||
Increase in skeletal muscle regeneration | Regulation of post-injury inflammatory response | [29] | |
Stem cell reprogramming: Induction of proliferation, differentiation and self-renewal | [21] | ||
Bone | Increase in osteoblastogenesis | Increases MSC differentiation towards the osteoblastic lineage favouring Runx2 expression | [30,37] |
Decreases PPARγ expression diminishing MSC differentiation towards the adipocytic phenotype | [36,37] | ||
Decrease in osteoclastogenesis | Negative regulation of RANKL expression by osteoblasts | [35] |
- Citation: McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World J Diabetes 2016; 7(6): 122-133
- URL: https://www.wjgnet.com/1948-9358/full/v7/i6/122.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i6.122